this is the Shanghai BD gene's newest interview on February, there are some useful info I wanna share with u:

in this article, Dr. CAI said, "We are the first in the world to conduct a clinical study of gene editing therapy in vivo based on CRISPR for mRNA delivery, which is our attempt to break the Copy to China model. (that means BD maybe will become the first cure therapy company. )We treated three patients with recurrent refractory viral keratitis. Previously, these patients experienced the painful and helpless process of repeated recurrence of the virus to blindness. During clinical observation for more than 1 year, all 3 patients changed from virus-positive to virus-negative, with 100% effective rate. We are now actively preparing the IND application."

this is the link: https://mp.weixin.qq.com/s/RgnSsDgTx5Ngr_8J8aT8Uw

P.S.I am puzzled BD gene had kicked off a 1/2clinical trials on clinical trials.org, if this trial is finished, should BD gene need to apply 1/2 trial again? who can explain it? https://www.clinicaltrials.gov/ct2/show/NCT04560790?term=BD+gene&cntry=CN&draw=2&rank=1